MX2022012705A - Metodos para tratar las infecciones por sars-cov-2. - Google Patents

Metodos para tratar las infecciones por sars-cov-2.

Info

Publication number
MX2022012705A
MX2022012705A MX2022012705A MX2022012705A MX2022012705A MX 2022012705 A MX2022012705 A MX 2022012705A MX 2022012705 A MX2022012705 A MX 2022012705A MX 2022012705 A MX2022012705 A MX 2022012705A MX 2022012705 A MX2022012705 A MX 2022012705A
Authority
MX
Mexico
Prior art keywords
cov
infections
methods
sars
treat sars
Prior art date
Application number
MX2022012705A
Other languages
English (en)
Spanish (es)
Inventor
Adrian Hepner
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2022012705A publication Critical patent/MX2022012705A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022012705A 2020-04-10 2021-04-08 Metodos para tratar las infecciones por sars-cov-2. MX2022012705A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US202063062599P 2020-08-07 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (1)

Publication Number Publication Date
MX2022012705A true MX2022012705A (es) 2022-11-07

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012705A MX2022012705A (es) 2020-04-10 2021-04-08 Metodos para tratar las infecciones por sars-cov-2.

Country Status (12)

Country Link
US (1) US12605364B2 (https=)
EP (1) EP4132518B1 (https=)
JP (1) JP2023521163A (https=)
KR (1) KR20230002371A (https=)
CN (1) CN115361947A (https=)
AU (1) AU2021253866A1 (https=)
BR (1) BR112022020193A2 (https=)
CA (1) CA3174710A1 (https=)
IL (1) IL296517A (https=)
MX (1) MX2022012705A (https=)
WO (1) WO2021207443A1 (https=)
ZA (1) ZA202210474B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) * 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) * 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Also Published As

Publication number Publication date
CN115361947A (zh) 2022-11-18
KR20230002371A (ko) 2023-01-05
US20230144719A1 (en) 2023-05-11
ZA202210474B (en) 2025-12-17
WO2021207443A1 (en) 2021-10-14
AU2021253866A1 (en) 2022-10-20
JP2023521163A (ja) 2023-05-23
EP4132518A1 (en) 2023-02-15
IL296517A (en) 2022-11-01
US12605364B2 (en) 2026-04-21
EP4132518C0 (en) 2025-08-13
CA3174710A1 (en) 2021-10-14
BR112022020193A2 (pt) 2022-11-22
EP4132518B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
UY38696A (es) Moduladores de alfa-1 antitripsina
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
MX2024010140A (es) Nuevos metodos.
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MD4812B1 (ro) Derivaţi nucleozidici 4'-substituiţi în calitate de inhibitori ai transcriptazei inverse a HIV
MX389672B (es) Inhibidores de ssao de aminopirimidina
CR20240363A (es) Compuestos y métodos para el tratamiento de infecciones virales.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2024015576A (es) Tratamiento para migra?as
JOP20230157A1 (ar) طرق مُعالجة فيروس كورونا
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
CL2019001804A1 (es) Activador de nrf2.
MX2018012739A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2021012824A (es) Métodos para tratar el prurito.
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
MX392870B (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion.
MX2022012705A (es) Metodos para tratar las infecciones por sars-cov-2.
WO2021231931A8 (en) Methods of treating sars-cov-2 infections
EA201992233A1 (ru) Соединения изоксазолкарбоксамида и их применение
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций